Back to the WireInvesting.com
ConfirmedInvesting.com ·
Celldex discontinues atopic dermatitis program after trial miss
Celldex has discontinued its atopic dermatitis program after a clinical trial did not meet its goal, according to the headline. Holders should expect pipeline value to be reassessed following the setback.
Who is reporting it
- GlobeNewswirefirst at Nov 19, 2026, 4:01 PM ESTRead at GlobeNewswire (opens in a new tab)
- Investing.comfirst at Nov 19, 2026, 4:04 PM ESTRead at Investing.com (opens in a new tab)
Story so far
Reported by 2 sources
Celldex reported that its Phase 2 atopic dermatitis study of barzolvolimab missed its primary and key secondary endpoints, and it is discontinuing development in that indication.
- Nov 19, 2026, 4:01 PM EST · GlobeNewswireConfirmedCelldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
- Nov 19, 2026, 4:04 PM EST · Investing.com · this storyConfirmedCelldex discontinues atopic dermatitis program after trial miss
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.